Bibliography
- FRETLAND D, PENNING T: Recent advances in leukotri- ene Bg receptor antagonist research. Exp. Opin. Ther. Patents (1996) 6:21–28.
- •A review covering many of the patents claiming LTB4 recep-tor antagonists.
- SAWYER J: Leukotriene Bg receptor antagonists: recent clinical developments. Exp. Opin. Invest. Drugs (1996) 5:73–77.
- ••Excellent review of clinical trial data on the earliercompounds.
- LABAUDINIERE R, HILBOLL G, LEON-LOMELI A et al: Omega-[(omega-arylalkyflarylialkanoic acids: a new class of specific LTA4 hydrolase inhibitors. J. Med. Chem. (1992) 35:3156–3169.
- •Structure-activity relationship studies on a series of com-pounds culminating in RP-64966.
- PENNING TD, ASKONAS U, DJURIC SW et al: Kelator- phan and related analogs: potent and selective inhibi-tors of leukotriene Ag hydrolase. Bioorg. Med. Chem. Lett. (1995) 5:2517–2522.
- ••Searle's early efforts in identifying LTA4 hydrolase inhibitorsuch as SC–57461.
- VILLANI-PRICE D, BLOSS JL, TORKELSON AR et al.: The pharmacokinetic (PK) and pharmacodynamic (PD) evaluation of the leukotriene Ag hydrolase inhibitor SC-57461 in monkeys and dogs. Int. Congr. Inflamm. Res. Assoc. (1996). Abstract 83.
- BELL RL, SUMMERS JB, HARRIS RR: Leukotriene modula-tors as therapeutic agents in asthma and other inflam-matory diseases. Ann. Rep. Med. Chem. (1997) 32:91-100. Recent review covering the latest developments in methods of inhibiting the production and effects of both LTB4 and the cysteinyl leukotrienes.